Treatment of depression with Chai Hu Shu Gan San: A systematic review and meta-analysis of 42 randomized controlled trials

BMC Complementary and Alternative Medicine

Volumn 18, Issue 1, 2018, Pages

  Sun, Yan ^a,b   Xu, Xia ^a   Zhang, Jinping ^b   Chen, Yuanyuan ^c  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Nankai Hospital   (China)

^c Department of Ophthalmology   (China)

Author keywords

Chai Hu Shu Gan san; Depression; Randomized control trial; Systematic review

Indexed keywords

FLUOXETINE; HERBACEOUS AGENT;

ADVERSE OUTCOME; ARTICLE; CHINESE MEDICINE; DATA BASE; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; POST-STROKE DEPRESSION; POSTNATAL DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WESTERN MEDICINE; PHYTOTHERAPY; PSYCHOLOGY;

DEPRESSION; DRUGS, CHINESE HERBAL; HUMANS; PHYTOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85042165037     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-018-2130-z     Document Type: Article

References (59)

1. Hamet P, Tremblay J. Genetics and genomics of depression. Metabolism. 2005;54:10-5.
2. Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, Bunting B, Demyttenaere K, Florescu S, de Girolamo G, Gureje O, He Y, Hu C, Huang Y, Karam E, Kovess-Masfety V, Lee S, Levinson D, Medina Mora ME, Moskalewicz J, Nakamura Y, Navarro-Mateu F, Browne MA, Piazza M, Posada-Villa J, Slade T, Ten Have M, Torres Y, Vilagut G, Xavier M, Zarkov Z, Shahly V, Wilcox MA. Anxious and non-anxious major depressive disorder in the World Health Organization world mental health surveys, Epidemiol. Psychiatr Sci. 2015;24:210-26.
3. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al. Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2013;43:471-81.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
5. Stockholm: Swedish Council on Health Technology Assessment (SBU). Treatment of depression: a systematic review [internet]. 2004, SBU Yellow Report No. 166/1+2+3.
6. Higgins JPT, Altman DG, Sterne JAC. Cochrane handbook for systematic reviews of interventions version, Cochrane collaboration. 2011. http://training.cochrane.org/handbook. Accessed Mar 2011.
7. Chang XH, Zhang LZ. Fifty cases of post-stoke depression treatment with Chai Hu Shu Gan San, Liaoning. J Trad Chin Med. 2010;37:1973-4.
8. Chen HH, Liu Y, Shen XM. A clinical observation and mechanism study of post-stroke depression treatment with flavored Chai Hu Shu Gan San, Liaoning. J. Trad. Chin Med. 2013;40:112-4.
9. Cheng SY, Li L, Li JM. A clinical observation of depression treatment with traditional Chinese medicine applied consecutively, Liaoning. J. Trad Chin. Med. 2007;34:957-8.
10. Cui Y, Yang JB. Assessment of the therapeutic effectiveness of flavored chai Hu Shu Gan san for treating post-stroke depression, Guangming. J Chin. Med. 2016;31:74-7.
11. Fang XH, Wu Q, Han XM. A clinical study of Chaihu Shugan powder in the treatment of malignant tumor patients with depression. Journal of Chinese Oncology. 2013;19:726-9.
12. He XM, Zhang YK. A clinical observation of the therapeutic efficacy of the combination of flavored Chai Hu Shu Gan San and Prozac for the treatment of post-stroke depression. J New Chin Med. 2007;39:22-3.
13. Huang WX, Yin YH, Hu JJ. Thirty-two cases of treatment of post-cerebral infarction depression, Fujian. J. Trad Chin. Med. 2010;41:21-2.
14. Huang XB, Zhang GJ, Liu AH. A clinical observation of depression concomitant with seizures treated with a method for reducing phlegm reduction and relieving stagnation. China J Trad Chin Med Phar. 2015;30:4183-5.
15. Huang YS, Luo RH, Yuan ZX. A clinical observation of the treatment of post-stroke depression with flavored Chai Hu Shu Gan San. J Prac Trad Chin Med. 2012;26:36-7.
16. Li L, Lin XD. Clinical observation of Chai Hu Shu Gan San for treating chronic pelvic inflammation. Handan Medical College Newspaper. 2006;19:215-7.
17. Lian Z, Wu Q. An efficacy analysis of a combination of Chai Hu Shu Gan San and fluoxetine in treating post-stroke depression, Guangming. J Chin Med. 2009;24:101-2.
18. Lin B, Xia J. A clinical study of Jia Wei Chai Hu Shu Gan San for treating depression. J. New Chin. Med. 2011;43:36-7.
19. Liu LY, Wang PR, Gu CY. A combination of Chai Hu Shu Gan San and venlafaxine for treating depression due to liver and qi stagnation in a randomized control trials. Zhejiang Medical Education. 2012;11:51-3.
20. Ma YZ, Lan R. Thirty-six cases of Parkinson's disease concomitant with depression, Liaoning. J. Trad Chin. Med. 2011;38:119-20.
21. Qiu ZJ, Wang LY. Clinical study of modified Chaihu Shugan powder on HP positive Piman syndrome accompanied with depression. Mod Med J China. 2012;14:10-3.
22. Wang GL, Jin YB. A combination of Chai Hu Shu Gan San and paroxetine hydrochloride for treating moderate-severe post-stroke depression, chin. J Int Med. 2009;7:1428-9.
23. Wang RC, Zhu ZQ. Chai Hu Shu Gan San for treating depression. J Pract Trad Chin Med. 2013;29:258-9.
24. Wang YT, Zhao MJ, Li J. Chai, Hu Shu Gan San for treating post-PCI depression. Clin Res Prac. 2016;1:124.
25. Yang G, Gong XY. Chai Hu Shu Gan san for treating COPD concomitant with anxiety and depression. Guide of China Medicine. 2011;9:132-3.
26. Yao K, Liu SY. Chinese-western medicine combination for treating depression due to cerebral vascular disease. Guide of China Medicine. 2013;11:605-6.
27. Zhao XP, Lin H. A combination of fluoxetine and chai Hu Shu Gan San for treating postpartum depression, Liaoning. J Trad Chin Med. 2006;33:586-7.
28. Zhao Y, Li YX, Ling J. Effect of Chaihushugansan combined with fluoxetine on IL-6, IL-1β, TNF-α in postpartum depression. Chin J Biochem Pharm. 2016;4:127-9.
29. Zheng YJ, Wang ZY, Cao QX. Chai Hu Shu Gan San for treating GERD concomitant with depression, electronic. J Transl Med. 2016;3:49-50.
30. Zhou R, Chen KL, Wu ZM. A combination of duloxetine and Chai Hu Shu Gan San for treating Parkinson's disease concomitant with depression. Zhejiang J Int Trad Chin West Med. 2016;26:50-2.
31. Yuhan L. The randomized parallel contrast study about the clinical effect of combining treatment of bupleurum liver-coursing powder and western medicine on depressive coronary heart disease. Journal of Practical Traditional Chinese Internal Medicine. 2014;28(3):45-7.
32. Xueqing S. The clinical experience of Chai Hu Shu Gan San for treating 28 cases in depression. World Latest Medicine Information. 2016;16(53):181.
33. Guimei S. The clinical study on integrative medicine treating cerebrovascular disease concomitant with depression. Chin J Mod Drug Appl. 2014;8(17):91-2.
34. Xiaoxia G. Clinical observation on treating depression with Chaihu Shugan san plus mirtazapine tablets. Clinical Journal of Chinese Medicine. 2016;8(2):82-3.
35. Jun H. The clinical study on Chaihu Shugan in treating depression caused by a stagnation of liver qi. Asia-Pacific Traditional Medicine. 2015;11(6):125-6.
36. Peijue C. Clinical observation on the treatment of depressive symptoms and rheumatoid arthritis with Chaihu Shugan powder. Nei Mongol Journal of Traditional Chinese Medicine. 2015;2(2):1-2.
37. Chaoyang L. The effect analysis and safety evaluation of Chaihu Shugan powder combined amitriptyline to treat depression. Journal of Sichuan of Traditional Chinese Medicine. 2015;33(7):81-3.
38. Yang Y. Effect of Chaihu Shugan Jiawei on type 2 diabetes with depression related parameters. Journal of TCM University of Hunan. 2013;33(4):16-8.
39. Xianli J. Chaihu Shugan in treating 30 cases of depression caused by cerebrovascular disease. Henan Traditional Chinese Medicine. 2013;33(9):1445-6.
40. Shengzuo D. The observation on Chaihu Shugan Jiawei combined with citalopram in treating depression. China Modern Medicine. 2012;19(12):81-2.
41. Manju Y. The observation on Chaihu Shugan powder improving the depression situation caused by Parkinson's disease. Guangming Journal of Chinese Medicine. 2010;25(1):31-2.
42. Fenghua Z. The clinical observation on integrative medicine to treat the depression companied following cerebral infarction. J Guiyang Coll Tradit Chin Med. 2013;35(3):166-9.
43. Yingmin S. Shugan Jieyu of moving qi method in treating 30 cases of depression. Chinese Medicine Modern Distance Education of China. 2011;9(16):7.
44. Qiuli F. The clinical observation on integrative medicine in treating 70 cases of depression in old age. Shandong Journal of Traditional Chinese Medicine. 2008;27(4):259-60.
45. Guoxian P. The observation of Chai Hu Shu Gan powder in treating Cardioneurosis. Chinese Journal of Trauma and Disability Medicine. 2013;21(10):174-5.
46. Guanqing D. The clinical study on Chaihu Shugan powder Jiawei in treating dysthymic disorder. Shandong Journal of Traditional Chinese Medicine. 2013;9(32):635-6.
47. Liang W. Clinical observation on treating 30 cases of depression of liver qi stagnation type with Chaihu Shugan decoction. Journal of Practical Traditional Chinese Internal Medicine. 2012;26(1):67-8.
48. Maojin R. The clinical observation on Chaihu Shugan powder in treating post stroke depression. Health Care Today. 2015;2(2):218.
49. Mu HX, Liu J, Fatima S, Lin CY, Shi XK, Du B, Xiao HT, Fan BM, Bian ZX. Anti-inflammatory actions of (+)-3'α-Angeloxy-4'-keto-3',4'-dihydroseselin (Pd-Ib) against dextran sulfate sodium-induced colitis in C57BL/6 mice. J Nat Prod. 2016;79:1056-62.
50. Li DQ, Zhou L, Wang D, Wu J, Li LZ, Huang XX, Liu QB, Wu YY, Lin S, Yang JY, Song SJ, Wu CF. Neuroprotective oleanane triterpenes from the roots of Bupleurum Chinese. Bioorg Med Chem Lett. 2016;26:1594-8.
51. Gu LY, Chen Z, Zhao J, Ruan XJ, Zhao SY, Gao H. Antioxidant, anticancer and apoptotic effects of the Bupleurum Chinese root extract in HO-8910 ovarian cancer cells. J BUON. 2015;20:1341-9.
52. Song X, Ren T, Zheng Z, Lu T, Wang Z, Du F, Tong H. Anti-tumor and immunomodulatory activities induced by an alkali-extracted polysaccharide BCAP-1 from Bupleurum Chinese via NF-ΚB signaling pathway. Int J Biol Macromol. 2017;95:357-62.
53. Johari S, Joshi C, Gandhi T. Effect of Cyperus Rotundus on cytokine gene expression in experimental inflammatory bowel disease. Iran J Med Sci. 2016;41(5):391. PMID: 27582588.
54. Azimi A, Ghaffari SM, Riazi GH, Arab SS, Tavakol MM, Pooyan S. α-Cyperone of Cyperus Rotundus is an effective candidate for reduction of inflammation by destabilization of microtubule fibers in brain. J Ethnopharmacol. 2016;194:219-27.
55. Farahani K, Hashemi M. Investigating the effect of Hydroalcoholic extract of Cyperus Rotundus L. on the expression of Bcl-x1 Antiapoptotic gene in Rats' hippocampus tissue following global ischemic-reperfusion injury. Acta Med Iran. 2016;54:256-60.
56. Liu X, Li X, Ji S, Cui X, Li M. Screening of bioactive ingredients in Ligusticum chuanxiong Hort for protection against myocardial ischemia. Cell Physiol Biochem. 2016;40:770-80.
57. Cao S, Zhao W, Bu H, Zhao Y, Yu C. Ligustrazine for the treatment of unstable angina: a meta-analysis of 16 randomized controlled trials. Evid Based Complement Alternat Med. 2016;2016:8617062. PMID: 27213001.
58. Lin YL, Wang GJ, Huang CL, Lee YC, Liao WC, Lai WL, Lin YJ, Huang NK. Ligusticum chuanxiong as a potential neuroprotectant for preventing serum deprivation-induced apoptosis in rat pheochromocytoma cells: functional roles of mitogen-activated protein kinases. J Ethnopharmacol. 2009;122:417-23.
59. Lu C, Zhang J, Shi X, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, Miao Q, Wang S. Neuroprotective effects of tetramethylpyrazine against dopaminergic neuron injury in a rat model of Parkinson's disease induced by MPTP. Int J Biol Sci. 2014;10:350-7.